
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72195
10.1038/s41598-024-72195-4
Article
Exploring the therapeutic potential of interleukin-6 receptor blockade in cardiovascular disease treatment through Mendelian randomization
Ou Guangyang 1
Cai Huzhi 2
Yao Kunpeng 1
Qiu Zerui 1
Yang Yang 1
Chen Yaowu 1
Chen Xinyu cxysmyx@163.com

2
1 https://ror.org/02my3bx32 grid.257143.6 0000 0004 1772 1285 The First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410007 Hunan China
2 https://ror.org/05htk5m33 grid.67293.39 The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007 Hunan China
13 9 2024
13 9 2024
2024
14 2145224 4 2024
4 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Interleukin-6 (IL-6) plays a crucial role in the pathogenesis of cardiovascular disease (CVD), and IL-6 receptor (IL-6R) blockade has emerged as a promising therapeutic option. However, their specific therapeutic effects in different types of CVDs remain unclear. This study aimed to assess the efficacy of IL-6R blockade in the management of various CVDs, including hypertension (HTN), coronary heart disease (CHD), myocardial infarction (MI), atrial fibrillation (AF), and heart failure (HF). The Mendelian randomization (MR) approach was utilized to investigate the therapeutic impact of IL-6R blockade on HTN, CHD, MI, AF, and HF based on the genome-wide association study (GWAS) summary statistics. MR-Egger intercept test, Cochran's Q test, and leave-one-out analysis were used for sensitivity analysis to verify the reliability of the MR results. The Bonferroni method was used to correct for bias caused by multiple comparisons. Inverse variance weighted (IVW) results demonstrated that IL-6R blockade significantly influenced CHD (odds ratio (OR) = 0.757, 95% confidence interval (CI): 0.690 - 0.832, P = 5.804 × 10–9) and MI (OR = 0.840, 95% CI: 0.744 - 0.949, P = 0.005). However, IL-6R blockade had no significant effect on HTN (OR = 1.015, 95% CI: 0.950 - 1.084, P = 0.663), AF (OR = 0.905, 95% CI: 0.800 - 1.025, P = 0.116) and HF (OR = 1.012, 95% CI: 0.921 - 1.113, P = 0.805). Genetically predicted IL-6R blockade was associated with a protective effect on CHD and MI, but not HTN, AF and HF. This study's findings offer valuable insights for tailoring IL-6R blockade treatment for different types of CVD, and serve as a reference for future research.

Keywords

Interleukin-6 receptor blockade
Cardiovascular disease
Coronary heart disease
Myocardial infarction
Drug treatment
Mendelian randomization study
Subject terms

Cardiovascular diseases
Drug discovery
Cardiology
http://dx.doi.org/10.13039/501100002767 Department of Science and Technology of Hunan Province 2020TJ-N01 2019SK2321 Cai Huzhi Chen Xinyu http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 81704061, 81173213 Department of Chinese Medicine Education in ChinaNo.2022-75 Chen Xinyu issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Cardiovascular disease (CVD) is a leading cause of global mortality1 and poses a significant challenge to public health worldwide. It is projected that by 2030, the prevalence of CVD in the global population aged over 65 will continue to rise, making it the primary cause of non-infectious disease-related deaths globally2. Therefore, there is great significance in identifying new treatment strategies and targets for CVD.

The pathogenesis of CVD is multifaceted, involving genetic, environmental, lifestyle, and other factors3. In recent years, inflammation has been recognized as playing a pivotal role in the development of CVDs and has garnered considerable attention4–7. Interleukin-6 (IL-6) is a multifunctional cytokine involved in regulating various biological processes such as immune response, inflammatory processes, and hematopoiesis8. Recent studies have established close associations between IL-6 and the development of various CVDs including atherosclerosis, inflammatory responses following myocardial infarction (MI), and heart failure (HF)9,10, suggesting that IL-6 may represent a potential target for treating CVD.

IL-6 receptor (IL-6R) blockade is a biological agent that inhibits the IL-6 signaling pathway by blocking the binding of IL-6 to its receptor, thereby reducing inflammation and immune response11. Currently, IL-6R blockade has demonstrated favorable efficacy and safety in treating conditions such as rheumatoid arthritis (RA)12 and COVID-1913 . However, studies on their application and effectiveness in treating CVDs remain limited.

Mendelian randomization (MR) studies, as a method to assess the causal relationship between exposure and outcome using genetic variants as instrumental variables (IV)14, are able to partially overcome the limitations of traditional observational studies. By selecting genetic variants associated with IL-6R expression as IV, MR studies can more effectively evaluate the role of IL-6R blockade in the treatment of CVD and their potential causal relationships. This study aims to reveal the feasibility and effectiveness of IL-6R blockade as potential drug targets for hypertension (HTN), coronary heart disease (CHD), MI, atrial fibrillation (AF), and HF, and to provide more precise treatment strategies for the prevention and treatment of CVD.

Materials and Methods

Selection of IVs

The IL6R gene encodes the IL-6 receptor protein, which plays an important role in inflammation and immune responses. The serum level of C-reactive protein (CRP) is a reliable downstream biomarker of IL-6 signal transduction. Therefore, the association between single nucleotide polymorphisms (SNPs) within the IL6R gene region and CRP levels can reflect the functional status of the IL-6 signaling pathway. IL-6R blockade inhibits downstream signal transduction by blocking the binding of IL-6 to its receptor, thereby achieving the purpose of anti-inflammation. Therefore, to simulate the effect of IL-6R blockade, we obtained SNPs within a 100 kb range on both sides of the IL-6R locus gene (chromosome 1: 154377819 - 154441926) that are associated with CRP levels, to estimate the downstream effect of IL-6R blockades on CVD risk.

In this study, the summary data of CRP were from a study by Sakaue S et al.15, which included 353,466 Europeans and 19,057,467 SNPs, mainly from the UK Biobank. First, we screened SNPs that were strongly correlated with CRP levels with the condition of P < 5E-08. Secondly, to ensure the independence of IVs, we excluded the interference of linkage disequilibrium (LD) (KB = 100, R2 < 0.3). Given the limited number of SNPs available for analysis under more stringent thresholds, we selected a threshold of R2 < 0.3 based on previous MR analyses of drug targets16–19. This threshold not only ensures an adequate number of SNPs but also controls the potential influence of LD. Finally, this study only considered common SNPs with an effect allele frequency (EAF) > 0.01. Through this process, we can more accurately simulate the effect of IL-6R blockades and thereby accurately estimate the downstream effect of IL-6R blockades on the risk of CVDs.

Besides, the selection of SNPs in MR analysis was based on three core assumptions: (1) SNPs must be strongly associated with the exposure variables; (2) SNPs should be independent of any potential confounders; and (3) SNPs influence the outcome solely through the exposure variables20.

Additionally, in order to ensure the stability of the results, we acquired additional GWAS data for CRP from the IEU Open GWAS project (204,402 Europeans) and conducted a repeated analysis using the aforementioned method to obtain IVs for IL-6R21. The data are mainly sourced from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Inflammation Working Group (CIWG)21, thereby avoiding the risk of sample overlap. The specific process of this study is illustrated in Fig. 1.Fig.1 Overview of the research workflow employed in this study. IL-6R, interleukin-6 receptor; CRP, C-reactive protein; CVD, cardiovascular disease; SNP, single nucleotide polymorphism; EAF, effect alleles frequency; IVW, inverse variance weighted; MR, mendelian randomization.

Source of results

This study analyzed the causal relationship between IL-6R blockade and five types of CVD, including HTN, CHD, MI, AF and HF. IL-6R blockade has been approved for the treatment of RA12, therefore RA was selected as a positive control in this study. All datasets used in this study were sourced from European populations to ensure demographic consistency. Furthermore, to avoid bias caused by sample overlap, the GWAS data for RA in this study were from an independent dataset provided by Okada Y et al.12. This dataset contains 14,361 RA cases and 43,923 controls, mainly from 18 European studies such as BRASS2, CANADA2, EIRA2, NARAC12, NARAC22, WTCCC2, Rheumatoid Arthritis Consortium International for Immunochip (RACI). The GWAS data for the five CVDs including CHD (51,098 cases and 402,635 controls), HF (33,250 cases and 420,483 controls), HTN (137,312 cases and 316,345 controls), MI (28,546 cases and 378,019 controls), and AF (55,853 cases and 231,952 controls) were obtained from the latest FinnGen consortium R11 version22. The data sources for this study are presented in Supplementary Table 1.

In this study, inverse variance weighted (IVW) was used as the main analysis method, and weighted median (WME) method, MR Egger method, weighted mode (WM) method and simple mode (SM) method were used for supplementary analyses. Given that the IV representing IL-6R blockade was weighted by CRP, the odds ratios (ORs) were proportional to the natural logarithm of the decrease in CRP.

The strength of IVs was evaluated using the F-statistic, with a value greater than 10 indicating no weak instrument bias23. Heterogeneity was assessed using Cochran’s Q statistics based on IVW and MR Egger methods24. In cases of heterogeneity, the inverse variance weighted multiplicative random effects (IVW-MRE) model was employed for MR Analysis25. Otherwise, the inverse variance weighted fixed effects (IVW-FE) model is applied. MR-Egger intercept test was used to detect pleiotropy, MR-PRESSO was used to identify and remove outliers, and leave-one-out sensitivity test was used to assess whether individual SNPs had a significant effect on the overall results.

All statistical analyses were performed using R 4.3.2 and the R package (TwoSampleMR and MR-PRESSO). To correct for bias due to multiple comparisons, P values were adjusted through Bonferroni correction with a significance threshold set at P < 0.01 (0.05/5 outcomes)26.

Results

Selection of IVs

After screening IVs as described above, a total of 44 SNPs were included for the MR Analysis between IL-6R blockade and CVDs and 10 SNPs were included for the repeated MR Analysis (Supplementary Table 2 and Supplementary Table 3). The F-statistics of the SNPs related to IL-6R blockade screened in this study ranged from 31.614 to 1002.100, and the F-statistics of the SNPs in the repeated analysis ranged from 38.554 to 744.476, indicating that the selected IVs were all highly associated with exposure.

Positive control analysis

As expected, the results of IVW-MRE showed that IL-6R blockade significantly reduced the risk of RA (OR = 0.407, 95% CI: 0.299 - 0.554, P = 1.084 × 10−8).

MR Analysis between IL-6R blockade and CVD

The IVW results showed that, after applying the Bonferroni correction (Bonferroni-corrected significance level: P-value < 0.01), IL-6R blockade had a significant effect on CHD (OR = 0.757, 95% CI: 0.690 - 0.832, P = 5.804 × 10–9) and MI (OR = 0.840, 95% CI: 0.744 - 0.949, P = 0.005) (Fig. 2 and Supplementary Table 4). However, IL-6R blockade had no significant effect on HTN (OR = 1.015, 95% CI: 0.950 - 1.084, P = 0.663), AF (OR = 0.905, 95% CI: 0.800 - 1.025, P = 0.116) and HF (OR = 1.012, 95% CI: 0.921 - 1.113, P = 0.805) (Supplementary Table 4). Furthermore, similar conclusions were drawn when repeating the analysis with the five CVDs using another GWAS dataset (Fig. 3 and Supplementary Table 5).Fig.2 Results of MR analysis between IL-6R blockade and CVDs. Nsnp, number of single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; WME, weighted median; IVW-FE, inverse variance weighted fixed effects; IVW-MRE, inverse variance weighted multiplicative random effects; SM, simple mode; WM, weighted mode. This figure shows the results of the MR analysis, namely that the IL-6R blockade has a protective effect on CHD and MI, but has no significant effect on HTN, AF and HF. RA is used as a positive control. The IVW is the primary analysis method. When heterogeneity is detected, the IVW-MRE method is used to reduce bias, otherwise, the IVW-FE method is applied. MR Egger, WM, SM, and WM serve as supplementary methods. Significance is determined by a Bonferroni-corrected IVW p-values < 0.01 and consistent OR directions across methods. In this picture, the dots represent the OR values and the line segments represent the 95% confidence intervals. An OR less than 1 represents a protective effect of IL-6R blockade, and an OR greater than 1 represents a risk effect of IL-6R blockade.

Fig.3 Results of MR analysis between IL-6R blockade and CVDs for repeated analysis. Nsnp, number of single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; WME, weighted median; IVW-FE, inverse variance weighted fixed effects; IVW-MRE, inverse variance weighted multiplicative random effects; SM, simple mode; WM, weighted mode. This figure shows the results of the repeated MR analysis after changing the data source of CRP, namely that the IL-6R blockade has a protective effect on CHD and MI, but has no significant effect on HTN, AF and HF. RA is used as a positive control. The IVW method is the primary analysis method. When heterogeneity is detected, the IVW-MRE method is used to reduce bias, otherwise, the IVW-FE method is applied. The MR Egger, WME, SM, and WM serve as supplementary methods. Significance is determined by a Bonferroni-corrected IVW p-values < 0.01 and consistent OR directions across methods. The dots represent the OR values and the line segments represent the 95% confidence intervals, where an OR less than 1 suggests a protective effect of IL-6R blockade, and an OR greater than 1 indicates an increased risk.

Sensitivity analysis

The MR-Egger intercept test indicated no horizontal pleiotropy in all the results of this study (P > 0.05). The Cochran’s Q test revealed heterogeneity in the MR analyses between IL-6R blockade and RA (IVW: Q = 25.713, P = 0.028), CHD (IVW: Q = 66.963, P = 0.011), HTN (IVW: Q = 66.109, P = 0.013), AF (IVW: Q = 76.512, P = 3.691 × 10−7) and MI (IVW: Q = 66.613, P = 0.012) . In the repeated analysis, heterogeneity was detected between IL-6R blockade and RA (IVW: Q = 18.266, P = 0.019), so we performed the MR analyses using the IVW-MRE method to eliminate bias caused by heterogeneity27. However, in the remaining MR analyses, we did not detect the existence of heterogeneity. Therefore, we used the IVW-FE method. The MR-PRESSO test results showed that outliers existed in the MR analyses between IL-6R blockade and RA (rs12083537 and rs2274988), and AF (rs116710125). In the repeated analysis, we detected outliers in the MR analyses of the IL-6R blockade and RA (rs10752641), CHD (rs11265608), AF (rs4129267), and MI (rs11265608). Therefore, we repeated the MR analysis after removing these outliers to ensure the robustness of the results. The results of sensitivity analysis are presented in Supplementary Table 6 and Supplementary Table 7. The leave-one-out analysis demonstrated that no individual SNP had a significant effect on the overall results across MR analyses between IL-6R blockade and RA, CHD, and MI (Fig. 4 and Fig. 5). In conclusion, it can be stated that the MR results of this study are robust.Fig.4 The leave-one-out analysis of IL-6R on RA and CVDs. (A)RA, (B) HTN, (C) CHD, (D) MI, (E) AF, (F) HF. This figure presents the leave-one-out sensitivity analysis of IL-6R on RA and CVDs, namely that in the MR analyses between IL-6R blockade and RA, CHD, and MI, no individual SNP has a significant influence on the overall results. Each plot displays the results of excluding one SNP at a time to test the robustness of the findings. The x-axis represents the MR leave-one-out sensitivity analysis estimates, while the y-axis lists the SNPs. The black dots indicate the effect estimates for each leave-one-out analysis, with horizontal lines showing the 95% confidence intervals. The red line represents the overall estimate without excluding any SNPs.

Fig.5 The leave-one-out analysis of IL-6R on RA and CVDs for repeated analyses. (A) RA, (B) HTN, (C) CHD, (D) MI, (E) AF, (F) HF. This figure displays the results of a repeated leave-one-out sensitivity analysis with alternative datasets, that is, in the repeated MR analyses between IL-6R blockade and RA, CHD and MI, no individual SNP had a significant influence on the overall results. In each plot, individual SNPs are excluded one at a time to assess the robustness of the results. The x-axis represents the MR leave-one-out sensitivity analysis estimates, while the y-axis lists the SNPs. The black dots indicate the effect estimates for each leave-one-out analysis, with horizontal lines representing the 95% confidence intervals. The red line represents the overall estimate without excluding any SNPs.

Discussion

The present study investigated the potential role of IL-6R blockade in the prevention and treatment of five types of CVD, including HTN, CHD, MI, AF, and HF, using MR methods. The results showed that the drug had a significant effect on the treatment of CHD and MI but had no obvious effect on the treatment of HTN, AF and HF. These findings provide an important basis for the clinical application of IL-6R blockade in the treatment of CVD and offer theoretical support and practical evidence for utilizing genetic information to guide precise CVD treatment.

First, the potential therapeutic effects of IL-6R blockade on CHD and MI may be related to their anti-inflammatory properties. Inflammation plays a crucial role in the occurrence and development of atherosclerosis as well as its related CVDs. The study by Held C et al.28 demonstrated that IL-6 was independently associated with the risk of major coronary events (hazard ratio (HR) 1.60, 95% CI: 1.30 - 1.97, P < 0.0001) and MI (HR: 1.53, 95% CI: 1.14 - 2.04, P < 0.05), and suggested that anti-inflammatory drugs targeting IL-6 might be a potential future target for the treatment of stable coronary heart disease. This result is consistent with our observation in this study that IL-6R blockade has a protective effect on the treatment of CHD and MI. Besides, previous studies have indicated that IL-6 is closely associated with the formation and progression of atherosclerotic plaques29,30. IL-6 can not only promote macrophage uptake of low-density lipoprotein leading to accelerated lipid particle deposition and foam cell formation but also enhance CD44 expression in macrophages while promoting positive feedback secretion of IL-6 by macrophages. This further exacerbates inflammatory responses by increasing vascular endothelial growth factor (VEGF) production resulting in intravascular atherosclerotic plaque formation. Therefore, we hypothesized that inhibition of IL-6 signaling by targeting IL-6R may reduce inflammatory responses, slow the progression of atherosclerosis, and have therapeutic effects on CHD and MI.

The results of this study indicated that there was no significant causal relationship between IL-6R blockade and AF. However, the study by Jing et al.31 showed that inhibiting IL-6 gene expression could significantly improve myocardial infarction-induced atrial fibrosis and myocardial remodeling. Gupta S et al.32 reported a reduced risk of AF in COVID-19 patients treated with tocilizumab compared to those not treated (9.0% vs 14.5%). Although some previous studies suggested that IL-6R blockade was associated with a reduced risk of AF, most of these studies were observational studies, which might be affected by reverse causality and potential confounding factors and could not provide definite causal inferences. Our MR analysis showed that there was no significant causal relationship between IL-6R blockade and AF, suggesting that the association observed in previous studies might only be a correlation rather than a causal relationship. However, since MR analysis also has its limitations, we believe that future studies require larger sample sizes and higher statistical power to explore the causal relationship between IL-6R and AF in a more powerful way.

Besides, this study failed to demonstrate a significant therapeutic effect of IL-6R blockade for HTN and HF. This may be due to the fact that the role of IL-6 in HTN and HF is not as direct or critical as it is in CHD and MI. For example, the development of HTN involves various mechanisms such as the renin-angiotensin system, sympathetic nerve activity, and vascular smooth muscle cell function33, suggesting that IL-6 may not play a major regulatory role in this process. This finding was supported by Gonzalez34, who observed that loss of IL-6 reduced myocardial inflammation and fibrosis, thereby improving cardiac function but did not prevent the development of HTN. Similarly, HF also involves complex mechanisms including abnormal calcium circulation, activation of neurohumoral system, myocardial cell injury, inflammatory response and ventricular remodeling35. These processes may be more regulated by other cytokines and signaling pathways. Additionally, studies on the correlation between IL-6R blockade and HF are limited and require further exploration in future research.

At the same time, this study has certain limitations. First of all, all the data in the study were from populations of European ancestry. Although this reduced the bias due to ethnic and regional differences, it also limited the generalizability of the study results to other ethnic groups. Therefore, our results are mainly applicable to populations of European ancestry, and the applicability to other ethnic groups is unknown. Secondly, the MR results rely on three assumptions, which may not always be fully achievable. Although we adopted various sensitivity analysis methods in the study, potential horizontal pleiotropy and potential confounding factors may still exist. Moreover, due to the limited number of SNPs available for analysis under more stringent thresholds, we chose a relatively relaxed R2 threshold of < 0.3. Although a few previous studies have employed a similar threshold, this is not a standard approach and may risk inflating results. Future studies should consider employing larger datasets that allow for the application of more stringent thresholds without compromising on the number of SNPs available for analysis. In addition, although we used multiple data sources to improve the robustness of the analysis and repeated MR analyses showed consistent results, future studies still require larger-scale clinical trials and in-depth mechanistic studies to verify and expand our findings. Finally, our study results are also limited by the coverage and quality of the existing GWAS datasets. With the increase in the availability of more high-quality genetic data from diverse populations, we will be able to estimate the impact of genetic variations on the risk of CVDs more accurately.

Conclusions

In summary, our study provides evidence from genetic proxies for the potential benefit of IL-6R blockade in the treatment of CHD and MI. At the same time, it also suggests that other therapeutic targets may need to be explored in the treatment of HTN, AF and HF. Future studies should further investigate the therapeutic mechanism of IL-6R blockade in different CVDs and evaluate their safety and efficacy in clinical application.

Supplementary Information

Supplementary Information 1.

Supplementary Tables.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72195-4.

Acknowledgements

We sincerely thank the investigators who provided the summary data on GWAS.

Author contributions

G.O., H.C. and K.Y designed the study. Z.Q., Y.Y. and Y.C. analyzed and interpreted the data. G.O. and X.C. wrote the manuscript and revised the manuscript. All authors approve of the final version of the manuscript.

Funding

This study was funded by National Natural Science Foundation of China (81704061, 81173213), the National Famous Elderly Chinese Medicine Expert Chen Xinyu Inheritance Workshop Construction Project [National Chinese Medicine Human Education Letter (2022) No. 75], the R & D Plan for Key Areas of Hunan Provincial Department of Science and Technology (2019SK2321) and the Hunan Science and Technology Talent Hosting Project (2020TJ-N01).

Data availability

The datasets supporting this study are available from GWAS Catalog (https://www.ebi.ac.uk/gwas/), FinnGen consortium (https://www.finngen.fi/en) and the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/). Corresponding author Xinyu Chen will provide the data upon reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Roth GA Johnson C Abajobir A Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 J. Am. Coll. Cardiol. 2017 70 1 1 25 10.1016/j.jacc.2017.04.052 28527533
Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70(1), 1–25 (2017).28527533 10.1016/j.jacc.2017.04.052
2. Ferdinandy P Andreadou I Baxter GF Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning Pharmacol. Rev. 2023 75 1 159 216 10.1124/pharmrev.121.000348 36753049
Ferdinandy, P. et al. Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning. Pharmacol. Rev. 75(1), 159–216 (2023).36753049 10.1124/pharmrev.121.000348
3. Frąk W Wojtasińska A Lisińska W Młynarska E Franczyk B Rysz J pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease Biomedicines 2022 10 8 1938 10.3390/biomedicines10081938 36009488
Frąk, W. et al. pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. Biomedicines 10(8), 1938 (2022).36009488 10.3390/biomedicines10081938
4. Suzuki K Chronic inflammation as an immunological abnormality and effectiveness of exercise Biomolecules 2019 9 6 223 10.3390/biom9060223 31181700
Suzuki, K. Chronic inflammation as an immunological abnormality and effectiveness of exercise. Biomolecules 9(6), 223 (2019).31181700 10.3390/biom9060223
5. Prabhu SD Frangogiannis NG the biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis Circ. Res. 2016 119 1 91 112 10.1161/CIRCRESAHA.116.303577 27340270
Prabhu, S. D. & Frangogiannis, N. G. the biological basis for cardiac repair after myocardial infarction: From inflammation to fibrosis. Circ. Res. 119(1), 91–112 (2016).27340270 10.1161/CIRCRESAHA.116.303577
6. Del Pinto R Ferri C Inflammation-accelerated senescence and the cardiovascular system: Mechanisms and perspectives Int. J. Mo.l Sci. 2018 19 12 3701 10.3390/ijms19123701
Del Pinto, R. & Ferri, C. Inflammation-accelerated senescence and the cardiovascular system: Mechanisms and perspectives. Int. J. Mo.l Sci. 19(12), 3701 (2018).10.3390/ijms19123701
7. Ruparelia N Choudhury R Inflammation and atherosclerosis: What is on the horizon Heart 2020 106 1 80 85 10.1136/heartjnl-2018-314230 31843811
Ruparelia, N. & Choudhury, R. Inflammation and atherosclerosis: What is on the horizon. Heart 106(1), 80–85 (2020).31843811 10.1136/heartjnl-2018-314230
8. Hunter CA Jones SA IL-6 as a keystone cytokine in health and disease Nat. Immunol. 2015 16 5 448 457 10.1038/ni.3153 25898198
Hunter, C. A. & Jones, S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 16(5), 448–457 (2015).25898198 10.1038/ni.3153
9. Ridker PM Rane M Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease Circ. Res. 2021 128 11 1728 1746 10.1161/CIRCRESAHA.121.319077 33998272
Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease. Circ. Res. 128(11), 1728–1746 (2021).33998272 10.1161/CIRCRESAHA.121.319077
10. Kaptoge S Di Angelantonio E Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction N. Engl. J. Med. 2012 367 14 1310 1320 10.1056/NEJMoa1107477 23034020
Kaptoge, S. et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N. Engl. J. Med. 367(14), 1310–1320 (2012).23034020 10.1056/NEJMoa1107477
11. Rose-John S Interleukin-6 Family Cytokines Cold Spring Harb. Perspect Biol. 2018 10 2 a028415 10.1101/cshperspect.a028415 28620096
Rose-John, S. Interleukin-6 Family Cytokines. Cold Spring Harb. Perspect Biol. 10(2), a028415 (2018).28620096 10.1101/cshperspect.a028415
12. Okada Y Wu D Trynka G Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature 2014 506 7488 376 381 10.1038/nature12873 24390342
Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488), 376–381 (2014).24390342 10.1038/nature12873
13. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021. 397(10285) 1637–1645.
14. Davies NM Holmes MV Davey SG Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians BMJ. 2018 362 k601 10.1136/bmj.k601 30002074
Davies, N. M., Holmes, M. V. & Davey, S. G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ. 362, k601 (2018).30002074 10.1136/bmj.k601
15. Sakaue S Kanai M Tanigawa Y A cross-population atlas of genetic associations for 220 human phenotypes Nat. Genet. 2021 53 10 1415 1424 10.1038/s41588-021-00931-x 34594039
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53(10), 1415–1424 (2021).34594039 10.1038/s41588-021-00931-x
16. Hu X Zhang P Gao Y Identification of lipid-modifying drug targets for autoimmune diseases: Insights from drug target mendelian randomization Lipids Health Dis. 2024 23 1 193 10.1186/s12944-024-02181-2 38909219
Hu, X. et al. Identification of lipid-modifying drug targets for autoimmune diseases: Insights from drug target mendelian randomization. Lipids Health Dis. 23(1), 193 (2024).38909219 10.1186/s12944-024-02181-2
17. Su Y Zhang Y Xu J Genetic variations in anti-diabetic drug targets and COPD risk: Evidence from mendelian randomization BMC Pulm. Med. 2024 24 1 240 10.1186/s12890-024-02959-1 38750544
Su, Y., Zhang, Y. & Xu, J. Genetic variations in anti-diabetic drug targets and COPD risk: Evidence from mendelian randomization. BMC Pulm. Med. 24(1), 240 (2024).38750544 10.1186/s12890-024-02959-1
18. Duan H Shi Y Zhang Q Causal relationship between PCSK9 inhibitor and primary glomerular disease: A drug target Mendelian randomization study Front. Endocrinol. (Lausanne). 2024 15 1335489 10.3389/fendo.2024.1335489 38510702
Duan, H. et al. Causal relationship between PCSK9 inhibitor and primary glomerular disease: A drug target Mendelian randomization study. Front. Endocrinol. (Lausanne). 15, 1335489 (2024).38510702 10.3389/fendo.2024.1335489
19. Huang A Wu X Lin J Wei C Xu W Genetic insights into repurposing statins for hyperthyroidism prevention: A drug-target Mendelian randomization study Front. Endocrinol. (Lausanne). 2024 15 1331031 10.3389/fendo.2024.1331031 38425755
Huang, A., Wu, X., Lin, J., Wei, C. & Xu, W. Genetic insights into repurposing statins for hyperthyroidism prevention: A drug-target Mendelian randomization study. Front. Endocrinol. (Lausanne). 15, 1331031 (2024).38425755 10.3389/fendo.2024.1331031
20. Birney E Mendelian Randomization Cold Spring Harb. Perspect Med. 2022 12 4 a041302 34872952
Birney, E. Mendelian Randomization. Cold Spring Harb. Perspect Med. 12(4), a041302 (2022).34872952
21. Ligthart S Vaez A Võsa U Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders Am. J. Hum. Genet. 2018 103 5 691 706 10.1016/j.ajhg.2018.09.009 30388399
Ligthart, S. et al. Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders. Am. J. Hum. Genet. 103(5), 691–706 (2018).30388399 10.1016/j.ajhg.2018.09.009
22. Kurki MI Karjalainen J Palta P FinnGen provides genetic insights from a well-phenotyped isolated population Nature 2023 613 7944 508 518 10.1038/s41586-022-05473-8 36653562
Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613(7944), 508–518 (2023).36653562 10.1038/s41586-022-05473-8
23. Sanderson E Glymour MM Holmes MV Mendelian randomization Nat. Rev. Methods Prim. 2022 2 6 10.1038/s43586-021-00092-5
Sanderson, E. et al. Mendelian randomization. Nat. Rev. Methods Prim. 2, 6 (2022).10.1038/s43586-021-00092-5
24. Greco MFD Minelli C Sheehan NA Thompson JR Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome Stat. Med. 2015 34 21 2926 2940 10.1002/sim.6522 25950993
Greco, M. F. D., Minelli, C., Sheehan, N. A. & Thompson, J. R. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat. Med. 34(21), 2926–2940 (2015).25950993 10.1002/sim.6522
25. Bowden J Spiller W Del Greco MF Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression Int. J. Epidemiol. 2018 47 4 1264 1278 10.1093/ije/dyy101 29961852
Bowden, J. et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int. J. Epidemiol. 47(4), 1264–1278 (2018).29961852 10.1093/ije/dyy101
26. Sedgwick P Multiple hypothesis testing and Bonferroni's correction BMJ. 2014 349 g6284 10.1136/bmj.g6284 25331533
Sedgwick, P. Multiple hypothesis testing and Bonferroni’s correction. BMJ. 349, g6284 (2014).25331533 10.1136/bmj.g6284
27. Papadimitriou N Dimou N Tsilidis KK Physical activity and risks of breast and colorectal cancer: A Mendelian randomisation analysis Nat. Commun. 2020 11 1 597 10.1038/s41467-020-14389-8 32001714
Papadimitriou, N. et al. Physical activity and risks of breast and colorectal cancer: A Mendelian randomisation analysis. Nat. Commun. 11(1), 597 (2020).32001714 10.1038/s41467-020-14389-8
28. Held C White HD Stewart R Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (Stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial J Am Heart Assoc. 2017 6 10 e005077 10.1161/JAHA.116.005077 29066452
Held, C. et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: Experiences from the STABILITY (Stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial. J Am Heart Assoc. 6(10), e005077 (2017).29066452 10.1161/JAHA.116.005077
29. Tardif JC Kouz S Waters DD Efficacy and safety of low-dose colchicine after myocardial infarction N. Engl. J. Med. 2019 381 26 2497 2505 10.1056/NEJMoa1912388 31733140
Tardif, J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381(26), 2497–2505 (2019).31733140 10.1056/NEJMoa1912388
30. Okazaki S Sakaguchi M Miwa K Association of interleukin-6 with the progression of carotid atherosclerosis: A 9 year follow-up study Stroke. 2014 45 10 2924 2929 10.1161/STROKEAHA.114.005991 25139874
Okazaki, S. et al. Association of interleukin-6 with the progression of carotid atherosclerosis: A 9 year follow-up study. Stroke. 45(10), 2924–2929 (2014).25139874 10.1161/STROKEAHA.114.005991
31. Jing R Long TY Pan W Li F Xie QY IL-6 knockout ameliorates myocardial remodeling after myocardial infarction by regulating activation of M2 macrophages and fibroblast cells Eur. Rev. Med. Pharmacol. Sci. 2019 23 14 6283 6291 31364133
Jing, R., Long, T. Y., Pan, W., Li, F. & Xie, Q. Y. IL-6 knockout ameliorates myocardial remodeling after myocardial infarction by regulating activation of M2 macrophages and fibroblast cells. Eur. Rev. Med. Pharmacol. Sci. 23(14), 6283–6291 (2019).31364133
32. Gupta S Wang W Hayek SS Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19 JAMA Intern. Med. 2021 181 1 41 51 10.1001/jamainternmed.2020.6252 33080002
Gupta, S. et al. Association between early treatment with tocilizumab and mortality among critically Ill patients with COVID-19. JAMA Intern. Med. 181(1), 41–51 (2021).33080002 10.1001/jamainternmed.2020.6252
33. Guzik TJ Touyz RM Oxidative stress, inflammation, and vascular aging in hypertension Hypertension 2017 70 4 660 667 10.1161/HYPERTENSIONAHA.117.07802 28784646
Guzik, T. J. & Touyz, R. M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 70(4), 660–667 (2017).28784646 10.1161/HYPERTENSIONAHA.117.07802
34. González GE Rhaleb NE D'Ambrosio MA Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension J. Hypertens. 2015 33 1 144 152 10.1097/HJH.0000000000000358 25304471
González, G. E. et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension. J. Hypertens. 33(1), 144–152 (2015).25304471 10.1097/HJH.0000000000000358
35. Braunwald E Heart failure JACC Heart Fail. 2013 1 1 1 20 10.1016/j.jchf.2012.10.002 24621794
Braunwald, E. Heart failure. JACC Heart Fail. 1(1), 1–20 (2013).24621794 10.1016/j.jchf.2012.10.002
